Table 4.
Multivariate Cox proportional hazards model to determine predictors of progression-free survival in patient treated with CDK4/6is pus ET.
| Variables | MV-HR | 95% CI | P value |
|---|---|---|---|
| Histology (compared to IDC) | |||
| ILC | 1.36 | 0.94–1.73 | 0.118 |
| Mixed | 0.86 | 0.46–1.45 | 0.604 |
| Race (compared to White) | |||
| Black | 0.91 | 0.65–1.24 | 0.583 |
| Hispanic | 1.05 | 0.74–1.46 | 0.740 |
| ET backbone (compared to AI) | |||
| Fulvestrant | 1.19 | 0.96–1.46 | 0.094 |
CDK4/6is cyclin-dependent kinase 4 and 6 inhibitors, ET endocrine therapy, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, Mixed mixed invasive ductal and lobular carcinoma, AI aromatase inhibitor, MV-HR multivariate hazard ratio, CI confidence interval.